Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV.

Gynecol Oncol. 2010 Jan;116(1):15-20. doi: 10.1016/j.ygyno.2009.09.025.

3.

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

Grushko TA, Filiaci VL, Mundt AJ, Ridderstråle K, Olopade OI, Fleming GF; Gynecologic Oncology Group..

Gynecol Oncol. 2008 Jan;108(1):3-9.

4.

Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.

Vandenput I, Vanden Bempt I, Leunen K, Neven P, Berteloot P, Moerman P, Vergote I, Amant F.

Gynecol Obstet Invest. 2009;67(1):46-8. doi: 10.1159/000161568.

PMID:
18843183
5.

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.

Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S.

Int J Gynaecol Obstet. 2008 Aug;102(2):128-31. doi: 10.1016/j.ijgo.2008.04.008.

PMID:
18555254
7.

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.

Lara PN Jr, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR; California Cancer Consortium..

Clin Lung Cancer. 2004 Jan;5(4):231-6.

PMID:
14967075
8.

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.

Growdon WB, Groeneweg J, Byron V, DiGloria C, Borger DR, Tambouret R, Foster R, Chenna A, Sperinde J, Winslow J, Rueda BR.

Gynecol Oncol. 2015 Apr;137(1):160-6. doi: 10.1016/j.ygyno.2015.01.533.

9.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M.

J Clin Oncol. 2002 Feb 1;20(3):719-26.

PMID:
11821453
10.

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P.

J Clin Oncol. 2005 Apr 1;23(10):2162-71.

PMID:
15800309
11.

Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.

Buza N, Hui P.

Genes Chromosomes Cancer. 2013 Dec;52(12):1178-86. doi: 10.1002/gcc.22113.

PMID:
24123408
12.

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

Conlin AK, Seidman AD, Bach A, Lake D, Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, Clawson A, Hudis CA.

Clin Breast Cancer. 2010 Aug 1;10(4):281-7. doi: 10.3816/CBC.2010.n.036.

13.

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.

Buza N, English DP, Santin AD, Hui P.

Mod Pathol. 2013 Dec;26(12):1605-12. doi: 10.1038/modpathol.2013.113.

14.

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM.

BMC Cancer. 2009 Dec 10;9:433. doi: 10.1186/1471-2407-9-433.

15.

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG.

Gynecol Oncol. 2012 Nov;127(2):345-50. doi: 10.1016/j.ygyno.2012.07.127.

16.

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.

Buza N, Roque DM, Santin AD.

Arch Pathol Lab Med. 2014 Mar;138(3):343-50. doi: 10.5858/arpa.2012-0416-RA. Review.

PMID:
24576030
17.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.

J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865.

PMID:
21172893
18.

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Yeon CH, Pegram MD.

Invest New Drugs. 2005 Oct;23(5):391-409. Review.

PMID:
16133791
19.

Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.

Koskas M, Depreeuw J, Moens S, Annibali D, Cuppens T, Moerman P, Lambrechts D, Amant F.

Anticancer Res. 2016 Oct;36(10):5381-5384.

PMID:
27798902
20.

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group..

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.

Items per page

Supplemental Content

Support Center